These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 22868251

  • 1. Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors.
    Gianazza E, Chinello C, Mainini V, Cazzaniga M, Squeo V, Albo G, Signorini S, Di Pierro SS, Ferrero S, Nicolardi S, van der Burgt YE, Deelder AM, Magni F.
    J Proteomics; 2012 Dec 05; 76 Spec No.():125-40. PubMed ID: 22868251
    [Abstract] [Full Text] [Related]

  • 2. Identification of potential serum proteomic biomarkers for clear cell renal cell carcinoma.
    Yang J, Yang J, Gao Y, Zhao L, Liu L, Qin Y, Wang X, Song T, Huang C.
    PLoS One; 2014 Dec 05; 9(11):e111364. PubMed ID: 25368985
    [Abstract] [Full Text] [Related]

  • 3. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
    Sandim V, Pereira Dde A, Kalume DE, Oliveira-Carvalho AL, Ornellas AA, Soares MR, Alves G, Zingali RB.
    Urol Oncol; 2016 Jan 05; 34(1):5.e11-25. PubMed ID: 26420021
    [Abstract] [Full Text] [Related]

  • 4. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
    Xu G, Xiang CQ, Lu Y, Kang XN, Liao P, Ding Q, Zhang YF.
    Cancer Lett; 2009 Sep 18; 282(2):205-13. PubMed ID: 19362769
    [Abstract] [Full Text] [Related]

  • 5. SELDI-TOF-MS-based serum proteomic screening in combination with CT scan distinguishes renal cell carcinoma from benign renal tumors and healthy persons.
    Xu G, Xiang CQ, Lu Y, Wang WJ, Kang XN, Liao P, Ding Q, Zhang YF.
    Technol Cancer Res Treat; 2009 Jun 18; 8(3):225-30. PubMed ID: 19445540
    [Abstract] [Full Text] [Related]

  • 6. Tumor size, stage and grade alterations of urinary peptidome in RCC.
    Chinello C, Cazzaniga M, De Sio G, Smith AJ, Grasso A, Rocco B, Signorini S, Grasso M, Bosari S, Zoppis I, Mauri G, Magni F.
    J Transl Med; 2015 Oct 20; 13():332. PubMed ID: 26482227
    [Abstract] [Full Text] [Related]

  • 7. [Proteomic analysis in combination with CT diagnosis to distinguish renal cell carcinoma from renal benign masses].
    Xu G, Xiang CQ, Lu Y, Kang XN, Wang WJ, Liao P, Ding Q, Zhang YF.
    Zhonghua Yi Xue Za Zhi; 2008 Mar 25; 88(12):858-60. PubMed ID: 18756995
    [Abstract] [Full Text] [Related]

  • 8. Differential expression and clinical significance of serum protein among patients with clear-cell renal cell carcinoma.
    Nuerrula Y, Rexiati M, Liu Q, Wang YJ.
    Cancer Biomark; 2015 Mar 25; 15(4):485-91. PubMed ID: 26406868
    [Abstract] [Full Text] [Related]

  • 9. Histology-guided proteomic analysis to investigate the molecular profiles of clear cell Renal Cell Carcinoma grades.
    Stella M, Chinello C, Cazzaniga A, Smith A, Galli M, Piga I, Grasso A, Grasso M, Del Puppo M, Varallo M, Bovo G, Magni F.
    J Proteomics; 2019 Jan 16; 191():38-47. PubMed ID: 29698802
    [Abstract] [Full Text] [Related]

  • 10. Screening for the serum differential proteins of renal cell carcinoma using magnetic beads-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Liu JS, Li HZ, Zhang YS, Wang P, Yan WG, Xie J, Dong DX.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Jun 16; 33(3):287-91. PubMed ID: 21718612
    [Abstract] [Full Text] [Related]

  • 11. iTRAQ-Based Quantitative Proteomic Analysis Identified HSC71 as a Novel Serum Biomarker for Renal Cell Carcinoma.
    Zhang Y, Cai Y, Yu H, Li H.
    Biomed Res Int; 2015 Jun 16; 2015():802153. PubMed ID: 26425554
    [Abstract] [Full Text] [Related]

  • 12. Differencial proteome of clear-cell renal cell carcinoma (ccRCC) tissues.
    Vieira de Ribeiro AJ, Sandim V, Ornellas AA, Reis RS, Domont G, Alves G.
    Int Braz J Urol; 2013 Jun 16; 39(1):83-94. PubMed ID: 23510786
    [Abstract] [Full Text] [Related]

  • 13. Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery.
    Boccardo F, Rubagotti A, Nuzzo PV, Argellati F, Savarino G, Romano P, Damonte G, Rocco M, Profumo A.
    Int J Cancer; 2015 Nov 15; 137(10):2394-402. PubMed ID: 25994113
    [Abstract] [Full Text] [Related]

  • 14. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.
    Hortin GL.
    Clin Chem; 2006 Jul 15; 52(7):1223-37. PubMed ID: 16644871
    [Abstract] [Full Text] [Related]

  • 15. Serum biomarkers of renal cell carcinoma assessed using a protein profiling approach based on ClinProt technique.
    Chinello C, Gianazza E, Zoppis I, Mainini V, Galbusera C, Picozzi S, Rocco F, Galasso G, Bosari S, Ferrero S, Perego R, Raimondo F, Bianchi C, Pitto M, Signorini S, Brambilla P, Mocarelli P, Galli Kienle M, Magni F.
    Urology; 2010 Apr 15; 75(4):842-7. PubMed ID: 19963255
    [Abstract] [Full Text] [Related]

  • 16. Liquid chromatography-mass spectrometry based serum peptidomic approach for renal clear cell carcinoma diagnosis.
    Huang Z, Zhang S, Hang W, Chen Y, Zheng J, Li W, Xing J, Zhang J, Zhu E, Yan X.
    J Pharm Biomed Anal; 2014 Nov 15; 100():175-183. PubMed ID: 25168216
    [Abstract] [Full Text] [Related]

  • 17. Identification of novel serum peptides biomarkers for female breast cancer patients in Western China.
    Yang J, Xiong X, Liu S, Zhu J, Luo M, Liu L, Zhao L, Qin Y, Song T, Huang C.
    Proteomics; 2016 Mar 15; 16(6):925-34. PubMed ID: 26705257
    [Abstract] [Full Text] [Related]

  • 18. iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma.
    Zhang L, Jiang H, Xu G, Chu N, Xu N, Wen H, Gu B, Liu J, Mao S, Na R, Jing Y, Ding Q, Zhang Y, Wang L.
    Biosci Trends; 2016 Jul 19; 10(3):210-9. PubMed ID: 27319973
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of Protein Profiling in a Cohort of Egyptian Population with Renal Cell Carcinoma and Benign Kidney Neoplasms.
    Kandil NS, Ghazala RA, El Sharkawy RM, Youssif TA, Noha Abouseda N.
    Asian Pac J Cancer Prev; 2019 Jul 01; 20(7):2145-2152. PubMed ID: 31350978
    [Abstract] [Full Text] [Related]

  • 20. The differential diagnostic model for serous peptidomics in HBV carriers established by MALDI-TOF-MS analysis.
    Tian L, Wang Y, Xu D, Gao Y, Wen X, Tian Y.
    Clin Biochem; 2014 Jan 01; 47(1-2):56-62. PubMed ID: 24183880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.